Onkológia 2/2021

Systemic treatment of local advanced non resekability or metastatic urothelial carcinoma

Combination platinum-based chemotherapy is the standard of care for first-line treatment of advanced or metastatic urothelial carcinoma. Although initial response rates are relatively high (around 50%), the median survival is about 15 months. Immunotherapy, particularly with antibodies directed against the programmed cell death 1 protein (PD-1) or its ligand (PD-L1) is new treatment option with clinicaly meanigfull outcomes in second-line therapy. Another novel strategy is maintenance with PD-L1 inhibitor Avelumab for patients who do not progress with first-line. Overview of current treatment options are reviewed here.

Keywords: chemotherapy, immunotherapy, urothelial carcinoma